Besides the pro-angiogenic VEGF molecule, another target in the treatment of macular edema is the RPE cells, which form the outer blood-retina barrier and incur damage and impairment of normal functions in diabetic patients. The gene discussed is VEGFA; the disease is macular retinal edema.